Intro offer
100 days of Premium for just $10.
Try all Premium features for over 3 months and analyze stocks without limits.
Try 100 days for $10

$0.71
10.56%
Nasdaq, Tue, Sep 15 2026.
ISIN
US00887A1051
Symbol
ALRN

Aileron Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation

Aileron Therapeutics, Inc. Classifications & Recommendation

Buy
78%
Hold
22%

Aileron Therapeutics, Inc. Price Target

Target Price $6.12
Price $0.71
Potential
Number of Estimates 4
4 Analysts have issued a price target Aileron Therapeutics, Inc. 2027 . The average Aileron Therapeutics, Inc. target price is $6.12. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 7 Analysts recommend Aileron Therapeutics, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Aileron Therapeutics, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Aileron Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -1.96 -0.45
44.16% 77.04%
P/E negative

4 Analysts have issued a Aileron Therapeutics, Inc. forecast for earnings per share. The average Aileron Therapeutics, Inc. EPS is

$-0.45
unlock
. This is
39.19% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.37 50.00%
unlock
, the lowest is
$-0.52 29.73%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-1.96 44.16%
2026
$-0.45 77.04%
unlock
2027
$-0.42 6.67%
unlock
2028
$-0.55 30.95%
unlock

P/E ratio

Current -0.96 96.04%
2026
-1.58 65.25%
unlock
2027
-1.69 6.96%
unlock
2028
-1.30 23.08%
unlock

Current Aileron Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 18 2026
Maxim Group
Locked
Locked
Locked Jul 20 2026
HC Wainwright & Co.
Locked
Locked
Locked Jun 01 2026
Brookline Capital
Locked
Locked
Locked Jan 21 2026
HC Wainwright & Co.
Locked
Locked
Locked Sep 22 2025
Brookline Capital
Locked
Locked
Locked Aug 19 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 18 2026
Locked
Maxim Group:
Locked
Locked
Jul 20 2026
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 01 2026
Locked
Brookline Capital:
Locked
Locked
Jan 21 2026
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 22 2025
Locked
Brookline Capital:
Locked
Locked
Aug 19 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today